Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.
INI Research Institute and Clinics, Grottaferrata, Rome, Italy. puoti@epatologia.org.
Claudio
C
Puoti
INI Research Institute and Clinics, Grottaferrata, Rome, Italy.
Gaetano
G
Lanzetta
INI Research Institute and Clinics, Grottaferrata, Rome, Italy.
Emilio
E
Scotti
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000821:virology*; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000821:virology*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a